Phase I study of pemetrexed, cisplatin, and concurrent radiotherapy in patients with locally advanced non-small cell lung cancer

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 35, Issue 2, 2012, Pages 115-119

  Li, Bao Sheng ^a   Gong, He Yi ^a   Huang, Wei ^a   Yi, Yan ^a   Yu, Jin Mimg ^a   Wang, Zhong Tang ^a   Zhang, Zi Cheng ^a   Sun, Hong Fu ^a   Li, Hong Sheng ^a   Wang, Li Ying ^a  

^a SHANDONG CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

Chemoradiotherapy; Cisplatin; Late course accelerated hyperfractionated IMR.T.; Non small cell lung cancer; Pemetrexed

Indexed keywords

CISPLATIN; FLUORODEOXYGLUCOSE F 18; PEMETREXED; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; GLUTAMIC ACID DERIVATIVE; GUANINE;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; BOLUS INJECTION; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER REGRESSION; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ESOPHAGITIS; FEMALE; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LUNG NON SMALL CELL CANCER; LUNG SCINTISCANNING; MALE; MAXIMUM TOLERATED DOSE; NAUSEA AND VOMITING; RADIATION DOSE; RECOMMENDED DRUG DOSE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT RESPONSE; TUMOR VOLUME; CANCER STAGING; CHEMORADIOTHERAPY; CLINICAL TRIAL; DRUG ADMINISTRATION; LUNG TUMOR; MIDDLE AGED; PATHOLOGY; PHASE 1 CLINICAL TRIAL; RADIATION DOSE FRACTIONATION; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMORADIOTHERAPY; CISPLATIN; DOSE FRACTIONATION; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; RADIOTHERAPY, INTENSITY-MODULATED; TREATMENT OUTCOME;

EID: 84860672040     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e318209ab93     Document Type: Article

References (35)

1. Parkin DM, Bray FI, Devessa SS. Cancer burden for the year 2000: The global picture. Eur J Cancer. 2001;37:S4-S66.
2. Novello S, LeChevalier T. Chemotherapy for non-small cell lung cancer. Part 1: Early stage disease. Oncology (Huntingt). 2003;17:357-364.
3. Spira A, Ettinger DS. Multidisciplinary management of lung cancer. N Engl J Med. 2004;350:379-392. (Pubitemid 38101633)
4. Furuse K, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol. 1999;17:2692-2699. (Pubitemid 29415225)
5. Machtay M, Hsu C, Komaki R, et al. Effect of overall treatment time on outcomes after concurrent chemoradiation for locally advanced non-small-cell lung carcinoma: Analysis of the Radiation Therapy Oncology Group (RTOG) experience. Int J Radiat Oncol Biol Phys. 2005;63:667-671. (Pubitemid 41400050)
6. Marino P, Preatoni A, Cantoni A. Randomized trials of radiotherapy alone versus combined chemotherapy and radiotherapy in stages IIIa and IIIb nonsmall cell lung cancer: A meta-analysis. Cancer. 1995;76:593-601.
7. Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: Update 2003. J Clin Oncol. 2004;22:330-353.
8. Pritchard RS, Anthony SP. Chemotherapy plus radiotherapy compared with radiotherapy alone in the treatment of locally advanced, unresectable, nonsmall cell lung cancer: A metaanalysis. Ann Intern Med. 1996;125:723-729. (Pubitemid 126450359)
9. Vokes EE, Crawford J, Bogart J, et al. Concurrent chemoradiotherapy for unresectable stage III non-small cell lung cancer. Clin Cancer Res. 2005;11:5045s-5050s.
10. Fournel P, Robinet G, Thomas P, et al. Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique- Groupe Francais de Pneumo-Cancerologie NPC 95-01 Study. J Clin Oncol. 2005;23:5910-5917.
11. Curran W, Scott CJ, Langer C, et al. Long-term benefit is observed in a phase III comparison of sequential vs concurrent chemoradiation for patients with unresected stage III NSCLC: RTOG 9410. Proc Am Soc Clin Oncol. 2003;22:621.
12. Schild SE, Wong WW, Vora SA, et al. The long-term results of a pilot study of three times a day radiotherapy and escalating doses of daily cisplatin for locally advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2005;62:1432-1437. (Pubitemid 40982066)
13. Kim YS, Yoon SM, Choi EK, et al. Phase II study of radiotherapy with three-dimensional conformal boost concurrent with paclitaxel and cisplatin for stage IIIB non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2005;62:76-81. (Pubitemid 40591926)
14. Movsas B, Scott C, Langer C, et al. Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: Radiation therapy oncology group trial 98-01. J Clin Oncol. 2005;23:2145-2154. (Pubitemid 46218706)
15. Sugawara T. Multiple fractions per day radiotherapy: Its background and current status. J Jpn Soc Ther Radiol Oncol. 1997;9:263-276.
16. Withers HR, Taylor JMG, Maciejewski B. The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol. 1988;27:131-146.
17. Rusthoven J, Eisenhauer E, Butts C, et al. Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced nonsmall cell lung cancer: A phase II study-National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1999;17:1194-1199. (Pubitemid 29162943)
18. Smit E, Mattson K, von Pawel J, et al. ALIMTA (pemetrexed disodium) as second-line treatment of non-small cell lung cancer: A phase II study. Ann Oncol. 2003;14:455-460. (Pubitemid 36367425)
19. Vogelzang N, Rusthoven J, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21:2636-2644. (Pubitemid 46606305)
20. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-smallcell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004;22:1589-1597. (Pubitemid 41079796)
21. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage nonsmall- cell lung cancer. J Clin Oncol. 2008;26:3543-3551.
22. Shepherd FA, Dancey J, Arnold A, et al. Phase II study of pemetrexed antifolate, and cisplatin as first-line therapy in patients with advanced non-small-cell lung carcinoma: A study of the National Cancer Institute of Canada Trials Group. Cancer. 2001;92:595-600. (Pubitemid 32735195)
23. Bischof M,Weber KJ, Blatter J, et al. Interaction of pemetrexed disodium (ALIMTA,multitargeted antifolate) and irradiation in vitro. Int J Radiat Oncol Biol Phys. 2002;52:1381-1388. (Pubitemid 34302884)
24. Seiwert TY, Connell PP, Mauer AM, et al. A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic non-small cell lung or esophageal cancer. Clin Cancer Res. 2007;13:515-521.
25. Heinzerling J, Hughes R, Govindan R, et al. Toxicity and response of pemetrexed plus carboplatin or cisplatin with concurrent chest radiation therapy (CRT) for patients with locally advanced nonsmall cell lung cancer (LANSCLC): A phase I trial. Int J Radiat Oncol Biol Phys. 2009;75:S110.
26. Yuan S, Sun X, Yu J, et al. A randomized study of involved-field irradiation versus elective nodal irradiation in combination with concurrent chemotherapy for inoperable stage III nonsmall cell lung cancer. Am J Clin Oncol. 2007;30:239-244. (Pubitemid 46884142)
27. Hanauske AR, Chen V, Paoletti P, et al. Pemetrexed disodium: A novel antifolate clinically active against multiple solid tumors. Oncologist. 2001;6:363-373. (Pubitemid 32816541)
28. Zinner RG, Fosella FV, Gladish GW, et al. Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced non-small-cell lung cancer. Cancer. 2005;104:2449-2456. (Pubitemid 41691567)
29. Seppenwoolde Y, Muller SH, Theuws JC, et al. Radiation dose- effect relations and local recovery in perfusion for patients with non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2000;47:681-690. (Pubitemid 30317487)
30. Therasse P, Arbuck SG, Eisenhower EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92:205-216. (Pubitemid 30099779)
31. Govindan R, Bogart J, Wang X, et al. A phase II study of pemetrexed, carboplatin and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small cell lung cancer: CALGB 30407-early evaluation of feasibility and toxicity. J Clin Oncol. 2008;26(suppl): 7518.
32. Socinski MA, Blackstock AW, Bogart JA, et al. Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105. J Clin Oncol. 2008; 26: 2457-2463.
33. Iranzo V, Bremnes RM, Almendros P, et al. Induction chemotherapy followed by concurrent chemoradiation for patients with nonoperable stage III non-small-cell lung cancer. Lung Cancer. 2009;63:63-67.
34. Blanco R, Solé J, Montesinos J, et al. Induction chemotherapy with DDP and gemcitabine followed by concurrent chemoradiation with twice-weekly gemcitabine in unresectable stage III nonsmall cell lung cancer: Final results of a phase II study. Lung Cancer. 2008;62:62-71.
35. Vokes E, Senan S, Treat J, et al. A phase III study of pemetrexed, cisplatin, and radiation therapy followed by consolidation pemetrexed versus etoposide, cisplatin, and radiation therapy followed by consolidation cytotoxic chemotherapy of choice in locally advanced stage III non-small-cell lung cancer of other than predominantly squamous cell histology. Clin Lung Cancer. 2009;10:193-198.